NYSE$STVN
Stevanato Group S.p.A. · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Stevanato Q4 2024: €330.6M revenue (+3%), EPS €0.18, high-value solutions 40% of mix
Stevanato Group reported Q4 and fiscal 2024 results for the quarter ended December 31, 2024. Q4 revenue increased 3% (3% constant currency) to €330.6 million, driven by 7% growth in Biopharmaceutical and Diagnostic Solutions offsetting a 16% decline in Engineering. High-value solutions reached a record €131 million and 40% of revenue, led by premium syringes. Diluted EPS was €0.18 (adjusted €0.19); net profit was €48.3 million. Adjusted EBITDA rose 5% to €90.9 million with margin up 50 bps to 27.5%. Full-year revenue grew 2% to €1,104 million with high-value solutions up 15% to €422.3 million. FY2025 guidance calls for revenue of €1,160–1,190 million and adjusted diluted EPS of €0.51–0.55.
- Q4 revenue of €330.6 million increased 3% YoY; BDS segment grew 7% while Engineering declined 16%.
- Diluted EPS was €0.18 (adjusted €0.19) on net profit of €48.3 million.
- High-value solutions revenue reached a record €131 million, 40% of Q4 revenue.
- Adjusted EBITDA grew 5% to €90.9 million; adjusted EBITDA margin expanded 50 bps to 27.5%.
- FY2025 guidance: revenue €1,160–1,190M, adjusted diluted EPS €0.51–0.55.
Headline financials
Revenue & EPS history
Stevanato Group · Revenue · Quarterly
€331M
Revenue by segment
Stevanato Group · €462M total across 3 segments · Q4 2024
- Biopharmaceutical and Diagnostic Solutions€279M—60.5%
- High-value solutions€131M—28.4%
- Engineering€51.2M—11.1%
Forward guidance
FY2025 revenue guidance of €1,160–1,190 million, adjusted EBITDA €293.0–306.3 million, and adjusted diluted EPS €0.51–0.55.
Tailwinds
- Strong demand for high-performance syringes and biologics exposure at 34% of BDS revenue
- Engineering optimization plan on track for majority completion by mid-2025
Headwinds
- Vial destocking continues to pressure EZ-fill volumes and gross margin mix
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2024
+1.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+3.0%
Avg return
30 days after
58%
11 / 19 earnings
Positive
+22.3%
Q2 2021
Best reaction
-18.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +10.0% | +1.9% | -10.3% | |
| Q3 2025 | -1.7% | -3.3% | -11.6% | |
| Q2 2025 | -9.6% | -7.6% | -9.9% | |
| Q1 2025 | +2.9% | +12.0% | +8.9% | |
| Q4 2024 | +8.6% | +8.8% | +10.5% | |
| Q3 2024 | +16.4% | +12.4% | +3.9% | |
| Q2 2024 | +4.4% | +8.5% | +13.8% | |
| Q1 2024 | -18.9% | -20.7% | -30.8% | |
| Q4 2023 | -11.3% | -14.1% | -12.4% | |
| Q3 2023 | -5.9% | -2.5% | -3.5% | |
| Q2 2023 | +2.5% | +5.6% | +6.3% | |
| Q1 2023 | -3.3% | -1.5% | +2.6% | |
| Q4 2022 | +13.7% | +5.2% | +16.0% | |
| Q3 2022 | +0.4% | +9.1% | +18.0% | |
| Q2 2022 | +4.6% | -3.4% | -5.9% | |
| Q1 2022 | +0.7% | +8.7% | +11.2% | |
| Q4 2021 | -1.4% | -4.2% | +21.9% | |
| Q3 2021 | -8.7% | -11.2% | -4.8% | |
| Q2 2021 | +22.3% | +27.0% | +33.8% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro